Genzyme CVRs start trading; Incyte scores $15M milestone;

 @FierceBiotech: Westphal leaving SR One, concentrating on VC firm. News | Follow @FierceBiotech 

 @JohnCFierce: Inspire Pharma hit a wall in January when its CF drug flunked a Ph3. Merck is picking up the opthalmology pieces in the debris. | Follow @JohnCFierce

> Those CVRs Sanofi offered to complete the Genzyme acquisition started trading at $2.30. Story

> Incyte scored a $15 million milestone payment from Novartis based on the ongoing Phase I dose-escalation trial for INCB28060 (also known as INC280) in patients with solid tumors. Incyte release

> The FDA has approved an extended release version of Viramune, Boehringer's HIV drug. Story

> Champions Oncology has completed the private placement of 12.5 million shares of its common stock at a price of $0.75 per share, proving $9.4 million in financing. Report

Pharma News

@FiercePharma: Analysts: Expect more hostile bids in pharma. Story | Follow @FiercePharma

> Merck nabs eye specialist Inspire for $430M. Report

> Drugmakers: Canada-EU trade deal won't cost billions. Article

> Bankers expect more Japanese-led M&A. News

> Early hep C drug pricing spooks experts. Story

> Bayer to combine East Coast ops in NJ. Report

> Data questions Avastin safety for eye use. Article

Research News

> Former football player now studies athletes' genes. News

> Gene-patent courtroom drama plays out in Washington. Article

> Alzheimer's researchers have five new genes to ponder. Report

> Israeli biotech Pluristem uses stem cells from placentas. Story

> Nanoparticles provide protection against nickel allergies. Item

> Coming soon: 3D adult stem cells, no glasses required. Report

Manufacturing News

> India marks its fifth $1B drugmaker. Story

> Roche, Catalent suffer warehouse fires. Item

> McNeil consent decree quarantine helps J&J's bottom line. Report

> Merck, Roche add voice to pick operations. Article

> PAT, QbD spur continuous processing. News

> DNA links Lilly, GSK warehouse thefts. Report

And Finally... Investigators at UT Southwestern Medical Center say they have discovered how to block a dangerous spike in blood pressure often seen in patients suffering from hypertension when they exercise. Report

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.